These results surpass those of other weight loss drugs, such as semaglutide, which resulted in an average weight reduction of approximately 15% over the same period
New @Nature A quintuple [GLP-1 + 4 other] receptor agonist drug that exceeds effects of the dual receptor (GLP-1 and GIP, tirzepatide) in the experimental model vs diabetes and obesity (in case you thought a dual receptor was max effect, as also seen with retatrutide, a triple pic.twitter.com/bvjCbj5Y6P - Eric Topol (@EricTopol) April 29, 2026 Journal reference: Liskiewicz, D., Novikoff, A., Khalil, A
Nilsen, J., Sandlie, I., Roopenian, D
On that basis a 1 mL draw delivers about 125 mg combined MIC and ~1000 mcg B12, and a 0.5 mL draw delivers half of each
Clinical trials across autoimmune diseases indicate a potential role for metformin as an adjunct therapy